KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Current Deferred Revenue (2018 - 2025)

Historic Current Deferred Revenue for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $42.5 million.

  • Adaptive Biotechnologies' Current Deferred Revenue fell 4973.47% to $42.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.5 million, marking a year-over-year decrease of 4973.47%. This contributed to the annual value of $82.9 million for FY2024, which is 1121.57% down from last year.
  • As of Q3 2025, Adaptive Biotechnologies' Current Deferred Revenue stood at $42.5 million, which was down 4973.47% from $75.3 million recorded in Q2 2025.
  • Over the past 5 years, Adaptive Biotechnologies' Current Deferred Revenue peaked at $179.2 million during Q4 2021, and registered a low of $42.5 million during Q3 2025.
  • For the 5-year period, Adaptive Biotechnologies' Current Deferred Revenue averaged around $103.5 million, with its median value being $91.1 million (2024).
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first soared by 14442.5% in 2021, then plummeted by 4973.47% in 2025.
  • Over the past 5 years, Adaptive Biotechnologies' Current Deferred Revenue (Quarter) stood at $179.2 million in 2021, then plummeted by 31.53% to $122.7 million in 2022, then fell by 23.87% to $93.4 million in 2023, then fell by 11.22% to $82.9 million in 2024, then crashed by 48.71% to $42.5 million in 2025.
  • Its Current Deferred Revenue stands at $42.5 million for Q3 2025, versus $75.3 million for Q2 2025 and $79.6 million for Q1 2025.